RxDoctor Payments Data

Melody Boals

Psychiatric/Mental Health · Warren, OHNPI 1528793387

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 156 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$642
  • Johnson & Johnson$410
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$401
  • Alkermes, Inc.$351
  • Vanda Pharmaceuticals Inc.$280
  • Axsome Therapeutics, Inc.$272
  • plus $847 from 8 others

What the payments were for

  • Food & beverage$3,15398%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,203 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$13,573
Medicare patients
68
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate49$169,889
RexultiBrexpiprazole78$128,977
Invega TrinzaPaliperidone Palmitate16$125,408
IngrezzaValbenazine Tosylate15$116,455
AristadaAripiprazole Lauroxil34$94,259
VraylarCariprazine Hcl27$41,708
Aripiprazole263$20,578
TrintellixVortioxetine Hydrobromide36$17,525
Paliperidone ErPaliperidone92$15,820
Divalproex Sodium ErDivalproex Sodium108$11,656
QelbreeViloxazine Hcl11$11,261
Oxcarbazepine158$6,828
Clozapine101$6,697
Divalproex Sodium196$6,083
Duloxetine Hcl200$5,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$410$295,29765 claims
Otsuka America Pharmaceutical, Inc.Rexulti$193$128,97778 claims
Neurocrine Biosciences, Inc.Ingrezza$84$116,45515 claims
Alkermes, Inc.Aristada$351$94,25934 claims
AbbVieVraylar$642$41,70827 claims
Supernus Pharmaceuticals, Inc.Qelbree$36$11,26111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →